ACAM 2000

Drug Profile

ACAM 2000

Alternative Names: ACAM 1000; ACAM2000; Smallpox (vaccinia) live vaccine - Emergent BioSolutions; Smallpox (vaccinia) live vaccine - Sanofi Pasteur Biologics; Smallpox vaccine - Sanofi Pasteur Biologics

Latest Information Update: 27 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Acambis
  • Developer Emergent BioSolutions
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Smallpox

Most Recent Events

  • 21 Nov 2017 Registered for Smallpox (Prevention) in Australia (Transdermal)
  • 21 Nov 2017 Registered for Smallpox (Prevention) in Singapore (Transdermal)
  • 20 Nov 2017 The US FDA approves Emergent BioSolutions' supplemental Biologics License Application (sBLA) to manufacture ACAM 2000 in newly-acquired cGMP live viral manufacturing facility in Canton, Massachusetts
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top